Follow-up on the 2nd law discussed yesterday.
It is not by mistake that the 2 new drugs active in breast cancer, triple negative, target microtubules.
Indeed, both Erubilin and Ixabepilone target Microtubules.
I just took the test on Hope S. Rugo's presentation following the logic, passed the test without problem. So:
SHOULD WE USE CASPASE RELEASE IN LABORATORY AS PROOF OF CHEMOTHERAPY EFFECTIVENESS ON A STANDARD BASE (ROUTINELY), ON FRESHLY OBTAINED TISSUE, THAT IS!
Nature seems to tell us that when there is an error in the gene, we can repair this, but when the Microfilaments are destroyed, Mitosis is compromised and the cells' destiny is to die! This is where the power of Vinorelbine comes from...Vinorelbine-Cisplatin is used as standard therapy for lung cancer, particularly in other parts of the world!
DISCUSSION ON PARP INHIBITOR TO FOLLOW...
No comments:
Post a Comment